Molecular Characterization of Medulloblastoma in a Patient with Neurofibromatosis Type 1: Case Report and Literature Review.
Marco RanalliAlessandra BoniAnna Maria CaroleoGiada Del BaldoMartina RinelliEmanuele AgoliniSabrina RossiEvelina MieleGiovanna Stefania ColafatiLuigi BoccutoIside AlessiMaria Antonietta De IorisAntonella CacchioneRossella CapolinoAndrea CaraiSabina VennariniAngela MastronuzziPublished in: Diagnostics (Basel, Switzerland) (2021)
Brain tumors are the most common solid neoplasms of childhood. They are frequently reported in children with Neurofibromatosis type 1 (NF1). The most frequent central nervous system malignancies described in NF1 are optic pathway gliomas and brainstem gliomas. Medulloblastoma (MB) in NF1 patients is extremely rare, and to our knowledge, only 10 cases without molecular characterization are described in the literature to date. We report the case of a 14-year-old girl with NF1 that came to our attention for an incidental finding of a lesion arising from cerebellar vermis. The mass was completely resected, revealing a localized classic medulloblastoma (MB), subgroup 4. She was treated as a standard-risk MB with a dose-adapted personalized protocol. The treatment proved to be effective, with minor toxicity. Brain and spine MRI one year after diagnosis confirmed the complete remission of the disease. To our knowledge, this is the only case of MB reported in a patient with NF1 with molecular characterization by the methylation profile. The association between NF1 and MB, although uncommon, may not be an accidental occurrence.
Keyphrases
- signaling pathway
- lps induced
- oxidative stress
- pi k akt
- nuclear factor
- healthcare
- inflammatory response
- end stage renal disease
- systematic review
- case report
- magnetic resonance imaging
- randomized controlled trial
- chronic kidney disease
- lymph node
- young adults
- risk assessment
- peritoneal dialysis
- ejection fraction
- rheumatoid arthritis
- newly diagnosed
- patient reported outcomes
- blood brain barrier
- immune response
- brain injury
- contrast enhanced
- genome wide
- white matter
- clinical trial
- magnetic resonance
- resting state
- open label
- combination therapy
- disease activity